LDLR is an entry receptor for Crimean-Congo hemorrhagic fever virus.
Journal
Cell research
ISSN: 1748-7838
Titre abrégé: Cell Res
Pays: England
ID NLM: 9425763
Informations de publication
Date de publication:
05 Jan 2024
05 Jan 2024
Historique:
received:
26
09
2023
accepted:
14
12
2023
medline:
6
1
2024
pubmed:
6
1
2024
entrez:
5
1
2024
Statut:
aheadofprint
Résumé
Crimean-Congo hemorrhagic fever virus (CCHFV) is the most widespread tick-born zoonotic bunyavirus that causes severe hemorrhagic fever and death in humans. CCHFV enters the cell via clathrin-mediated endocytosis which is dependent on its surface glycoproteins. However, the cellular receptors that are required for CCHFV entry are unknown. Here we show that the low density lipoprotein receptor (LDLR) is an entry receptor for CCHFV. Genetic knockout of LDLR impairs viral infection in various CCHFV-susceptible human, monkey and mouse cells, which is restored upon reconstitution with ectopically-expressed LDLR. Mutagenesis studies indicate that the ligand binding domain (LBD) of LDLR is necessary for CCHFV infection. LDLR binds directly to CCHFV glycoprotein Gc with high affinity, which supports virus attachment and internalization into host cells. Consistently, a soluble sLDLR-Fc fusion protein or anti-LDLR blocking antibodies impair CCHFV infection into various susceptible cells. Furthermore, genetic knockout of LDLR or administration of an LDLR blocking antibody significantly reduces viral loads, pathological effects and death following CCHFV infection in mice. Our findings suggest that LDLR is an entry receptor for CCHFV and pharmacological targeting of LDLR may provide a strategy to prevent and treat Crimean-Congo hemorrhagic fever.
Identifiants
pubmed: 38182887
doi: 10.1038/s41422-023-00917-w
pii: 10.1038/s41422-023-00917-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
Ergonul, O. Crimean-Congo haemorrhagic fever. Lancet Infect. Dis. 6, 203–214 (2006).
pubmed: 16554245
pmcid: 7185836
doi: 10.1016/S1473-3099(06)70435-2
Bente, D. A. et al. Crimean-Congo hemorrhagic fever: history, epidemiology, pathogenesis, clinical syndrome and genetic diversity. Antiviral Res. 100, 159–189 (2013).
pubmed: 23906741
doi: 10.1016/j.antiviral.2013.07.006
Akinci, E., Bodur, H. & Leblebicioglu, H. Pathogenesis of Crimean-Congo hemorrhagic fever. Vector Borne Zoonotic Dis. 13, 429–437 (2013).
pubmed: 23663164
doi: 10.1089/vbz.2012.1061
Zivcec, M., Scholte, F. E. M., Spiropoulou, C. F., Spengler, J. R. & Bergeron, E. Molecular insights into Crimean-Congo hemorrhagic fever virus. Viruses 8, 106 (2016).
Hawman, D. W. & Feldmann, H. Recent advances in understanding Crimean-Congo hemorrhagic fever virus. F1000Res 7(F1000 Faculty Rev), 1715 (2018).
Mehand, M. S., Al-Shorbaji, F., Millett, P. & Murgue, B. The WHO R&D Blueprint: 2018 review of emerging infectious diseases requiring urgent research and development efforts. Antiviral Res. 159, 63–67 (2018).
pubmed: 30261226
pmcid: 7113760
doi: 10.1016/j.antiviral.2018.09.009
Hawman, D. W. & Feldmann, H. Crimean-Congo haemorrhagic fever virus. Nat. Rev. Microbiol. 21, 463–477 (2023).
pubmed: 36918725
pmcid: 10013989
doi: 10.1038/s41579-023-00871-9
Sanchez, A. J., Vincent, M. J., Erickson, B. R. & Nichol, S. T. Crimean-Congo hemorrhagic fever virus glycoprotein precursor is cleaved by furin-like and SKI-1 proteases to generate a novel 38-kilodalton glycoprotein. J. Virol. 80, 514–525 (2006).
pubmed: 16352575
pmcid: 1317557
doi: 10.1128/JVI.80.1.514-525.2006
Bergeron, E., Vincent, M. J. & Nichol, S. T. Crimean-Congo hemorrhagic fever virus glycoprotein processing by the endoprotease SKI-1/S1P is critical for virus infectivity. J. Virol. 81, 13271–13276 (2007).
pubmed: 17898072
pmcid: 2169102
doi: 10.1128/JVI.01647-07
Vincent, M. J. et al. Crimean-Congo hemorrhagic fever virus glycoprotein proteolytic processing by subtilase SKI-1. J. Virol. 77, 8640–8649 (2003).
pubmed: 12885882
pmcid: 167219
doi: 10.1128/JVI.77.16.8640-8649.2003
Hulswit, R. J. G., Paesen, G. C., Bowden, T. A & Shi, X. Recent advances in bunyavirus glycoprotein research: precursor processing, receptor binding and structure. Viruses 13, 353 (2021).
Li, N. et al. Cryo-EM structure of glycoprotein C from Crimean-Congo hemorrhagic fever virus. Virol. Sin. 37, 127–137 (2022).
pubmed: 35234630
pmcid: 8922431
doi: 10.1016/j.virs.2022.01.015
Mishra, A. K. et al. Structural basis of synergistic neutralization of Crimean-Congo hemorrhagic fever virus by human antibodies. Science 375, 104–109 (2022).
pubmed: 34793197
doi: 10.1126/science.abl6502
Bertolotti-Ciarlet, A. et al. Cellular localization and antigenic characterization of crimean-congo hemorrhagic fever virus glycoproteins. J. Virol. 79, 6152–6161 (2005).
pubmed: 15858000
pmcid: 1091677
doi: 10.1128/JVI.79.10.6152-6161.2005
Fels, J. M. et al. Protective neutralizing antibodies from human survivors of Crimean-Congo hemorrhagic fever. Cell 184, 3486–3501.e21 (2021).
pubmed: 34077751
pmcid: 8559771
doi: 10.1016/j.cell.2021.05.001
Simon, M., Johansson, C. & Mirazimi, A. Crimean-Congo hemorrhagic fever virus entry and replication is clathrin-, pH- and cholesterol-dependent. J. Gen. Virol. 90, 210–215 (2009).
pubmed: 19088291
doi: 10.1099/vir.0.006387-0
Garrison, A. R. et al. Crimean-Congo hemorrhagic fever virus utilizes a clathrin- and early endosome-dependent entry pathway. Virology 444, 45–54 (2013).
pubmed: 23791227
doi: 10.1016/j.virol.2013.05.030
Shtanko, O., Nikitina, R. A., Altuntas, C. Z., Chepurnov, A. A., Davey, R. A. Crimean-Congo hemorrhagic fever virus entry into host cells occurs through the multivesicular body and requires ESCRT regulators. PLoS Pathog. 10 (2014).
Connolly-Andersen, A. M., Magnusson, K. E. & Mirazimi, A. Basolateral entry and release of Crimean-Congo hemorrhagic fever virus in polarized MDCK-1 cells. J. Virol. 81, 2158–2164 (2007).
pubmed: 17166898
doi: 10.1128/JVI.02070-06
Monteil, V., Salata, C., Appelberg, S. & Mirazimi, A. Hazara virus and Crimean-Congo Hemorrhagic Fever Virus show a different pattern of entry in fully-polarized Caco-2 cell line. PLoS Negl. Trop. Dis. 14, e0008863 (2020).
pubmed: 33232320
pmcid: 7723249
doi: 10.1371/journal.pntd.0008863
Fuller, S., von Bonsdorff, C. H. & Simons, K. Vesicular stomatitis virus infects and matures only through the basolateral surface of the polarized epithelial cell line, MDCK. Cell 38, 65–77 (1984).
pubmed: 6088077
doi: 10.1016/0092-8674(84)90527-0
Moreira, E. A. et al. Synthetically derived bat influenza A-like viruses reveal a cell type- but not species-specific tropism. Proc. Natl. Acad. Sci. USA 113, 12797–12802 (2016).
pubmed: 27791106
pmcid: 5111703
doi: 10.1073/pnas.1608821113
Finkelshtein, D., Werman, A., Novick, D., Barak, S. & Rubinstein, M. LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus. Proc. Natl. Acad. Sci. USA 110, 7306–7311 (2013).
pubmed: 23589850
pmcid: 3645523
doi: 10.1073/pnas.1214441110
Gan, Y., McGraw, T. E. & Rodriguez-Boulan, E. The epithelial-specific adaptor AP1B mediates post-endocytic recycling to the basolateral membrane. Nat. Cell Biol. 4, 605–609 (2002).
pubmed: 12105417
doi: 10.1038/ncb827
Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819–823 (2013).
pubmed: 23287718
pmcid: 3795411
doi: 10.1126/science.1231143
Go, G. W. & Mani, A. Low-density lipoprotein receptor (LDLR) family orchestrates cholesterol homeostasis. Yale J. Biol. Med. 85, 19–28 (2012).
pubmed: 22461740
pmcid: 3313535
Willnow, T. E. et al. RAP, a specialized chaperone, prevents ligand-induced ER retention and degradation of LDL receptor-related endocytic receptors. EMBO J. 15, 2632–2639 (1996).
pubmed: 8654360
pmcid: 450198
doi: 10.1002/j.1460-2075.1996.tb00623.x
Clark, L. E. et al. VLDLR and ApoER2 are receptors for multiple alphaviruses. Nature 602, 475–480 (2022).
pubmed: 34929721
doi: 10.1038/s41586-021-04326-0
Xiao, X. D., Feng, Y., Zhu, Z. Y. & Dimitrov, D. S. Identification of a putative Crimean-Congo hemorrhagic fever virus entry factor. Biochem. Biophys. Res. Commun. 411, 253–258 (2011).
pubmed: 21723257
pmcid: 3155881
doi: 10.1016/j.bbrc.2011.06.109
Kita, T., Brown, M. S., Watanabe, Y. & Goldstein, J. L. Deficiency of low density lipoprotein receptors in liver and adrenal gland of the WHHL rabbit, an animal model of familial hypercholesterolemia. Proc. Natl. Acad. Sci. USA 78, 2268–2272 (1981).
pubmed: 6264472
pmcid: 319326
doi: 10.1073/pnas.78.4.2268
Lindquist, M. E. et al. Exploring Crimean-Congo hemorrhagic fever virus-induced hepatic injury using antibody-mediated type I interferon blockade in mice. J. Virol. 92, e01083-18 (2018).
Bente, D. A. et al. Pathogenesis and immune response of Crimean-Congo hemorrhagic fever virus in a STAT-1 knockout mouse model. J. Virol. 84, 11089–11100 (2010).
pubmed: 20739514
pmcid: 2953203
doi: 10.1128/JVI.01383-10
Bereczky, S. et al. Crimean-Congo hemorrhagic fever virus infection is lethal for adult type I interferon receptor-knockout mice. J. Gen. Virol. 91, 1473–1477 (2010).
pubmed: 20164263
doi: 10.1099/vir.0.019034-0
Zivcec, M. et al. Lethal Crimean-Congo hemorrhagic fever virus infection in interferon alpha/beta receptor knockout mice is associated with high viral loads, proinflammatory responses, and coagulopathy. J. Infect. Dis. 207, 1909–1921 (2013).
pubmed: 23417661
pmcid: 3654741
doi: 10.1093/infdis/jit061
Hawman, D. W. et al. Crimean-Congo hemorrhagic fever mouse model recapitulating human convalescence. J. Virol. 93, e00554-19 (2019).
Suda, Y. et al. Analysis of the entry mechanism of Crimean-Congo hemorrhagic fever virus, using a vesicular stomatitis virus pseudotyping system. Arch. Virol. 161, 1447–1454 (2016).
pubmed: 26935918
pmcid: 7087235
doi: 10.1007/s00705-016-2803-1
Dai, S. Y. et al. Differential cell line susceptibility to Crimean-Congo hemorrhagic fever virus. Front. Cell. Infect. Microbiol. 11, 648077 (2021).
Garcia, C. K. et al. Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science 292, 1394–1398 (2001).
pubmed: 11326085
doi: 10.1126/science.1060458
Charrel, R. N. et al. Tick-borne virus diseases of human interest in Europe. Clin. Microbiol. Infect. 10, 1040–1055 (2004).
pubmed: 15606630
doi: 10.1111/j.1469-0691.2004.01022.x
Bentzon, J. F. & Falk, E. Atherosclerotic lesions in mouse and man: is it the same disease? Curr. Opin. Lipidol. 21, 434–440 (2010).
pubmed: 20683327
doi: 10.1097/MOL.0b013e32833ded6a
Lanza-Jacoby, S. et al. Hyperlipoproteinemic low-density lipoprotein receptor-deficient mice are more susceptible to sepsis than corresponding wild-type mice. J. Endotoxin Res. 9, 341–347 (2003).
pubmed: 14733720
doi: 10.1177/09680519030090060701
Tall, A. R. & Yvan-Charvet, L. Cholesterol, inflammation and innate immunity. Nat. Rev. Immunol. 15, 104–116 (2015).
pubmed: 25614320
pmcid: 4669071
doi: 10.1038/nri3793
Atmosudigdo, I. S. et al. Dyslipidemia increases the risk of severe COVID-19: a systematic review, meta-analysis, and meta-regression. Clin. Med. Insights Endocrinol. Diabetes 14, 1179551421990675 (2021).
pubmed: 35173508
pmcid: 8842489
doi: 10.1177/1179551421990675
Louie, A. Y. et al. Dietary cholesterol causes inflammatory imbalance and exacerbates morbidity in mice infected with influenza A virus. J. Immunol. 208, 2523–2539 (2022).
pubmed: 35577367
doi: 10.4049/jimmunol.2100927
Agnello, V., Abel, G., Elfahal, M., Knight, G. B. & Zhang, Q. X. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc. Natl. Acad. Sci. USA 96, 12766–12771 (1999).
pubmed: 10535997
pmcid: 23090
doi: 10.1073/pnas.96.22.12766
Hofer, F. et al. Members of the low density lipoprotein receptor family mediate cell entry of a minor-group common cold virus. Proc. Natl. Acad. Sci. USA 91, 1839–1842 (1994).
pubmed: 8127891
pmcid: 43259
doi: 10.1073/pnas.91.5.1839
Albecka, A. et al. Role of low-density lipoprotein receptor in the hepatitis C virus life cycle. Hepatology 55, 998–1007 (2012).
pubmed: 22121002
doi: 10.1002/hep.25501
Yamamoto, S. et al. Lipoprotein receptors redundantly participate in entry of hepatitis C virus. PLoS Pathog. 12, e1005610 (2016).
pubmed: 27152966
pmcid: 4859476
doi: 10.1371/journal.ppat.1005610
Pileri, P. et al. Binding of hepatitis C virus to CD81. Science 282, 938–941 (1998).
pubmed: 9794763
doi: 10.1126/science.282.5390.938
Scarselli, E. et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 21, 5017–5025 (2002).
pubmed: 12356718
pmcid: 129051
doi: 10.1093/emboj/cdf529
Evans, M. J. et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446, 801–805 (2007).
pubmed: 17325668
doi: 10.1038/nature05654
Ploss, A. et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457, 882–886 (2009).
pubmed: 19182773
pmcid: 2762424
doi: 10.1038/nature07684
Ma, H. et al. LDLRAD3 is a receptor for Venezuelan equine encephalitis virus. Nature 588, 308–314 (2020).
pubmed: 33208938
pmcid: 7769003
doi: 10.1038/s41586-020-2915-3
Ganaie, S. S. et al. Lrp1 is a host entry factor for Rift Valley fever virus. Cell 184, 5163–5178.e24 (2021).
pubmed: 34559985
pmcid: 8786218
doi: 10.1016/j.cell.2021.09.001
Zhang, H. X. et al. TRIM27 mediates STAT3 activation at retromer-positive structures to promote colitis and colitis-associated carcinogenesis. Nat. Commun. 9, 3441 (2018).
pubmed: 30143645
pmcid: 6109048
doi: 10.1038/s41467-018-05796-z
Li, W. W. et al. Ubiquitination of TLR3 by TRIM3 signals its ESCRT-mediated trafficking to the endolysosomes for innate antiviral response. Proc. Natl. Acad. Sci. USA 117, 23707–23716 (2020).
pubmed: 32878999
pmcid: 7519224
doi: 10.1073/pnas.2002472117
Guo, R. et al. A new strain of Crimean-Congo hemorrhagic fever virus isolated from Xinjiang, China. Virol. Sin. 32, 80–88 (2017).
pubmed: 28251517
pmcid: 6598972
doi: 10.1007/s12250-016-3936-9
Li, S. et al. NSs filament formation is important but not sufficient for RVFV virulence in vivo. Viruses 11, 834 (2019).
Xia, H. et al. Characterization of Ebinur lake virus and its human seroprevalence at the China-Kazakhstan border. Front. Microbiol. 10, 3111 (2019).
pubmed: 32082268
doi: 10.3389/fmicb.2019.03111
Xu, Z. S. et al. FAM64A positively regulates STAT3 activity to promote Th17 differentiation and colitis-associated carcinogenesis. Proc. Natl. Acad. Sci. USA 116, 10447–10452 (2019).
pubmed: 31061131
pmcid: 6534998
doi: 10.1073/pnas.1814336116
REED, L. J. & Muench, H. A simple method of estimating fifty percent endpoints. Am. J. Epidemiol. 27, 493–497 (1938).
doi: 10.1093/oxfordjournals.aje.a118408
Zhang, R. et al. Mxra8 is a receptor for multiple arthritogenic alphaviruses. Nature 557, 570–574 (2018).
pubmed: 29769725
pmcid: 5970976
doi: 10.1038/s41586-018-0121-3
Wang, Q. et al. In vitro and in vivo efficacy of a novel nucleoside analog H44 against Crimean-Congo hemorrhagic fever virus. Antiviral Res. 199, 105273 (2022).
pubmed: 35257725
doi: 10.1016/j.antiviral.2022.105273